A cheaper-sounding, lesser-known cousin of creatine just outperformed the supplement aisle's gold standard on grip strength in adults over 65. Before you rewrite your stack, read the fine print: this was a tiny, 8-week pilot with 21 finishers, no exercise program, and confidence intervals that barely cleared zero. It is interesting and worth watching, but it is not a reason to ditch creatine monohydrate.
What Is GAA, and Why Compare It to Creatine?
Guanidinoacetic acid (GAA) is the immediate metabolic precursor of creatine. In the body, GAA is made in the kidney and then methylated in the liver to form creatine. That final step uses a methyl group donated by S-adenosylmethionine (SAMe).
The researchers' rationale is that aging may blunt creatine synthesis and transport. If so, supplying the precursor might bypass some of those bottlenecks and affect muscle energetics and protein metabolism differently than creatine itself. Creatine already helps older adults, particularly when paired with resistance training, but results without exercise are less consistent. That gap is where this trial aimed.
How the Study Was Run
The trial, published in the Journal of Nutritional Science and Vitaminology (2026;72(4):284-290), came from Ostojic's Applied Bioenergetics Lab and collaborators. It was randomized, double-blind, and explicitly labeled an exploratory pilot.
- Participants: 25 apparently healthy adults aged 65 or older were randomized; 21 completed (GAA n=11, creatine n=10).
- Intervention: 2.0 g/day of GAA versus an equimolar dose of creatine monohydrate for 8 weeks. By my rough math, that works out to about 2.5 g of creatine monohydrate, since the two compounds have different molecular weights.
- No structured exercise was part of the protocol.
- Outcomes: handgrip strength, body composition and fluid compartments via multifrequency bioelectrical impedance analysis (BIA), and blood markers including myostatin, IGF-1, mTOR, total homocysteine, albumin, and total protein.
Compliance exceeded 97% in both groups, and no adverse events were reported.
The Results: Grip Strength, Muscle Mass, Myostatin
Grip strength. Handgrip strength rose significantly with GAA (p=0.01) but not with creatine. The time-by-treatment interaction was significant (p=0.04), and the between-group effect was large in GAA's favor (Hedges' g=0.91). The 95% confidence interval ran from 0.00 to 1.81. That lower bound sitting right on zero means the true advantage could be anywhere from negligible to very large.
Body composition. On BIA, the GAA group showed significant within-group increases in fat-free mass, body cell mass, muscle mass, and total body water. The creatine group did not show comparable changes. Effect sizes generally leaned toward GAA for strength, muscle-related indices, and hydration-related compartments, though again with wide intervals.
Myostatin. Both supplements lowered circulating myostatin, a protein that restrains muscle growth, with greater suppression under GAA. Whether a blood myostatin shift translates into meaningful muscle changes in older adults is still an open question.
Other markers. Creatine produced a modest drop in serum albumin that stayed within the normal reference range. Serum IGF-1 was below the assay's detection limit in most participants, so the GH-IGF-1 axis could not be evaluated.
Caveats You Should Not Skip
Pilot size. With 10 to 11 people per arm, the study was not powered to settle anything. The authors themselves call the findings preliminary and hypothesis-generating.
BIA is not a scan. Bioelectrical impedance estimates muscle from electrical properties, and it is sensitive to hydration. Creatine is known to shift water into muscle, and the GAA group also showed increased total body water. So the "muscle mass" gains may partly reflect fluid. DXA or MRI would be a firmer test.
No exercise. The study asked what the supplements do on their own. Most real-world creatine benefit in older adults shows up alongside resistance training, so these results may not carry over to people who lift.
The homocysteine question. Because creatine synthesis from GAA consumes methyl groups, GAA has raised homocysteine in other studies. Elevated homocysteine is a cardiovascular and cognitive concern. This trial measured total homocysteine, but the abstract does not report a headline finding on it, so check the full paper before drawing conclusions. In practice, researchers working with GAA often point to adequate folate, B6, B12, and other methyl donors such as betaine as a sensible safeguard, especially in older adults who are more prone to low B12 status.
Short duration and wide intervals. Eight weeks tells us nothing about long-term safety or durability.
Practical Takeaways
- The dose studied was 2 g/day of GAA, versus an equimolar creatine monohydrate dose (about 2.5 g by my calculation).
- Who might eventually consider GAA: older adults who do not respond to creatine, or who are not exercising. That is speculation for now, and it is a conversation for a clinician, particularly for anyone with cardiovascular risk, kidney concerns, or low B-vitamin status.
- Why creatine monohydrate remains the default: it has decades of safety and efficacy data across many populations, it is inexpensive, and its benefits are best documented alongside resistance training. GAA has a small fraction of that evidence base and a plausible homocysteine trade-off.
- What would change this picture: larger, adequately powered trials in people with sarcopenia, using DXA or MRI, with homocysteine and B-vitamin status tracked and exercise arms included.
The Bottom Line
This pilot gives GAA a real, if tentative, headline: better grip strength than creatine in older adults over 8 weeks without exercise. But a confidence interval touching zero, 21 completers, and BIA-based muscle estimates add up to a signal worth following, not a verdict. For now, creatine monohydrate plus resistance training remains the proven play, and GAA is one to watch.
